J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...

An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...